Statistics for VYNE Therapeutics (id:6132 VYNE)
Valuation metrics
Market cap
42.78M
Enterprise value
-28,462,958.00
Trailing P/E (ttm)
0.88
Forward P/E
-3.33
PEG ratio
-3.33
Price/Sales (ttm)
86.77
Price/Book (mrq)
0.67
Enterprise Value/Revenue
-57.73
Enterprise Value/EBITDA
0.97
Overview
Shares outstanding
14.75M
Float
10.07M
Shares short
82.56K
% Held by insiders
0.08%
% Held by institutions
0.52%
Average volume (10 days)
96.37K
Average volume (90 days)
Price summary
52-Week low
1.57
52-Week high
4.09
52-Week change
-32.34%
Beta
1.35
50-Day moving average
2.33
200-Day moving average
2.26
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0.00%
Trailing annual dividend yield
0.00
5-Year annual dividend yield
Payout ratio
0.00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
February 13th, 2023
Financials
Fiscal yearFiscal year ends
December 31th, 2023
Most recent quarter (mrq)
September 30th, 2024
Profitability
Profit margin
0.00%
Operating margin
-10,819.01%
Operational effectiveness
Return on assets
-49.36%
Return on equity
-90.47%
Income statement
Revenue (ttm)
0.01
Revenue per share (ttm)
0.01
Quarterly revenue growth (yoy)
Gross profit (ttm)
0.00
EBITDA
0.00
Net income to common (ttm)
-34,094,000.00
Diluted EPS (ttm)
3.29
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
70.18M
Total cash per share (mrq)
4.76
Total debt (mrq)
123.00K
Total Debt/Equity (mrq)
0.19
Current ratio (mrq)
580.80%
Book value per share (mrq)
4.31
Cash flow
Cash flow statement
-25,087,000.00
Levered free cash flow (LFCF)
-28,452,000.00